Diseases, Conditions, Syndromes

New genetic link found for alcohol-related liver cirrhosis

In most people, any liver damage that might occur from drinking alcohol is reversible. However, in 25 to 30 percent of alcoholics what begins as accumulation of fat in the liver progresses to inflammation, fibrosis and ultimately ...

Diseases, Conditions, Syndromes

FDA approves mavyret for children, adolescents with hep C

(HealthDay)—Mavyret (glecaprevir and pibrentasvir) tablets are now approved to treat all six genotypes of hepatitis C virus (HCV) in children ages 12 to 17 years, the U.S. Food and Drug Administration announced yesterday.

Medical research

Researchers identify changes in cholesterol metabolic pathways

A new study from the Virginia Commonwealth University School of Medicine has identified molecular changes responsible for abnormal cholesterol production and metabolism in the livers of patients with a common liver condition, ...

Diseases, Conditions, Syndromes

Predicting the outcome of hepatitis C virus treatment

Millions of people throughout the world are infected with hepatitis C virus (HCV), which can lead to cirrhosis of the liver and cancer. Directly acting antiviral agents inhibit viral proteins and have been used to successfully ...

Medications

Daclatasvir for hepatitis C: Added benefit not proven

The drug daclatasvir (trade name Daklinza) has been available since August 2014 for the treatment of adults with chronic hepatitis C (CHC) infection. The German Institute for Quality and Efficiency in Health Care (IQWiG) ...

Diseases, Conditions, Syndromes

Mavyret approved as 8-week treatment for hep C, compensated cirrhosis

(HealthDay)—Approval of Mavyret (glecaprevir and pibrentasvir) tablets has been expanded to eight-week treatment for treatment-naive patients aged 12 years and older with chronic hepatitis C virus (HCV) genotypes 1 through ...

page 8 from 16